Detalhe da pesquisa
1.
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Breast Cancer Res Treat
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38767786